Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study

Kenji Suzuki, Yukinori Sameshima, Junji Yokoyama, Shuji Terai, Hiroyuki Yoneyama, Raja Atreya, Markus F. Neurath, Toshifumi Hibi, Hitoshi Asakura

Open source

DOI
10.1186/s41232-024-00332-7
Published
2024-04-25
Container
Inflammation and Regeneration
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s41232-024-00332-7,
  title = {Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study},
  author = {Kenji Suzuki and Yukinori Sameshima and Junji Yokoyama and Shuji Terai and Hiroyuki Yoneyama and Raja Atreya and Markus F. Neurath and Toshifumi Hibi and Hitoshi Asakura},
  year = {2024},
  journal = {Inflammation and Regeneration},
  doi = {10.1186/s41232-024-00332-7},
  url = {https://doi.org/10.1186/s41232-024-00332-7}
}

RIS

TY  - JOUR
TI  - Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study
AU  - Kenji Suzuki
AU  - Yukinori Sameshima
AU  - Junji Yokoyama
AU  - Shuji Terai
AU  - Hiroyuki Yoneyama
AU  - Raja Atreya
AU  - Markus F. Neurath
AU  - Toshifumi Hibi
AU  - Hitoshi Asakura
PY  - 2024
JO  - Inflammation and Regeneration
DO  - 10.1186/s41232-024-00332-7
UR  - https://doi.org/10.1186/s41232-024-00332-7
ER  - 

APA

Suzuki, K., Sameshima, Y., Yokoyama, J., Terai, S., Yoneyama, H., Atreya, R., Neurath, M. F., Hibi, T., & Asakura, H. (2024). Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study. Inflammation and Regeneration. https://doi.org/10.1186/s41232-024-00332-7

Source records